Iqvia (NYSE:IQV) Stock Price Up 9.7%

Iqvia Holdings Inc (NYSE:IQV)’s share price rose 9.7% during mid-day trading on Wednesday . The company traded as high as $97.09 and last traded at $106.30, approximately 82,838 shares traded hands during trading. A decline of 97% from the average daily volume of 2,821,958 shares. The stock had previously closed at $96.91.

IQV has been the subject of a number of recent analyst reports. Robert W. Baird increased their target price on shares of Iqvia from $172.00 to $181.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. SunTrust Banks lowered their price objective on shares of Iqvia from $184.00 to $128.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. JPMorgan Chase & Co. raised their price objective on shares of Iqvia from $180.00 to $195.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Stifel Nicolaus raised their price objective on shares of Iqvia from to and gave the company a “buy” rating in a research report on Wednesday, February 12th. Finally, Citigroup raised their price objective on shares of Iqvia from $185.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Iqvia currently has a consensus rating of “Buy” and a consensus price target of $169.06.

The firm’s 50-day moving average price is $137.77 and its 200 day moving average price is $147.00. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.05 and a current ratio of 1.05. The company has a market cap of $18.64 billion, a price-to-earnings ratio of 113.97, a PEG ratio of 1.05 and a beta of 0.94.

Iqvia (NYSE:IQV) last issued its quarterly earnings results on Wednesday, February 12th. The medical research company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.72 by $0.02. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. The company had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the company earned $1.50 EPS. Iqvia’s revenue was up 7.7% on a year-over-year basis. As a group, equities research analysts predict that Iqvia Holdings Inc will post 6.62 EPS for the current fiscal year.

In other news, Director John Connaughton sold 703,828 shares of Iqvia stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $164.30, for a total transaction of $115,638,940.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael R. Mcdonnell sold 12,000 shares of Iqvia stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the sale, the chief financial officer now owns 14,366 shares of the company’s stock, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. In the last quarter, insiders have sold 740,828 shares of company stock valued at $121,469,155. 6.00% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Sunbelt Securities Inc. bought a new position in Iqvia during the 4th quarter worth approximately $5,408,000. RMR Wealth Builders bought a new position in Iqvia during the 4th quarter worth approximately $27,000. Penserra Capital Management LLC boosted its stake in Iqvia by 57.5% during the 4th quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in Iqvia during the 4th quarter worth approximately $32,000. Finally, Patriot Financial Group Insurance Agency LLC boosted its stake in Iqvia by 379.5% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock worth $33,000 after acquiring an additional 167 shares during the last quarter. 89.25% of the stock is currently owned by institutional investors and hedge funds.

About Iqvia (NYSE:IQV)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: What is meant by holder of record?

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.